All currencies in US Dollar
JemalASiegelRWardE. Cancer statistics, 2009. CA Cancer J Clin2009;59:225–229.
BonelliLMartinesHConioM. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer1988;41:513–517.
AhsanHNeugutAIGarbowskiGC. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med1998;128:900–905.
GreeneFPageDFlemingIFritzA. AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002.
ComptonCCGreeneFL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin2004;54:295–308.
GreeneFLStewartAKNortonHJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg2002;236:416–421; discussion 421.
ComptonCC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med2000;124:1016–1025.
ComptonCC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med2006;130:318–324.
LaiLLFullerCDKachnicLAThomasCRJr. Can pelvic radiotherapy be omitted in select patients with rectal cancer?Semin Oncol2006;33(Suppl 11):S70–74.
NagtegaalIDMarijnenCAKranenbargEK. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol2002;26:350–357.
WibeARendedalPRSvenssonE. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg2002;89:327–334.
StocchiLNelsonHSargentDJ. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol2001;19:3895–3902.
Glynne-JonesRMawdsleySNovellJR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis2006;8:800–807.
AdamIJMohamdeeMOMartinIG. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet1994;344:707–711.
MawdsleySGlynne-JonesRGraingerJ. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?Int J Radiat Oncol Biol Phys2005;63:745–752.
NagtegaalIDQuirkeP. What is the role for the circumferential margin in the modern treatment of rectal cancer?J Clin Oncol2008;26:303–312.
SarliLBaderGIuscoD. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer2005;41:272–279.
NewlandRCDentOFLyttleMN. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer1994;73:2076–2082.
WongSLHongJHollenbeckBK. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA2007;298:2149–2154.
TepperJEO’ConnellMJNiedzwieckiD. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol2001;19:157–163.
PocardMPanisYMalassagneB. Assessing the effectiveness of mesorectal excision in rectal cancer: prognostic value of the number of lymph nodes found in resected specimens. Dis Colon Rectum1998;41:839–845.
WichmannMWMullerCMeyerG. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg2002;137:206–210.
BaxterNNMorrisAMRothenbergerDATeppeJE. Impact of pre-operative radiation for rectal cancer on subsequent lymph node evaluation: population based analysis. Int J Rad Oncol Biol Phys2005;61:426–431.
MeyersMOHollisDRMayerRJ. Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: an analysis of Intergroup 0114 [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4008.
TurnerRRNoraDTTrochaSDBilchikAJ. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med2003;127:673–679.
WoodTFNoraDTMortonDL. One hundred consecutive cases of sentinel node mapping in early colorectal carcinoma. Detection of micrometastasis. J Gastrointest Surg2002;6:322–330.
NouraSYamamotoHMiyakeY. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res2002;8:759–767.
YasudaKAdachiYShiraishiN. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol2001;8:300–304.
BraatAEOosterhuisJWMollFC. Sentinel node detection after preoperative short-course radiotherapy in rectal carcinoma is not reliable. Br J Surg2005;92:1533–1538.
BaselgaJRosenN. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol2008;26:1582–1584.
AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:1626–1634.
Khambata-FordSGarrettCRMeropolNJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol2007;25:3230–3237.
De RoockWPiessevauxHDe SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508–515.
PuntCJTolJRodenburgCJ. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract LBA 4011.
BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663–771.
TejparSPeetersMHumbletY. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4001.
Van CutsemEHenning-KohneCHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009; 36014:1408–1417.
LièvreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol2008;26:374–379.
KarapetisCSKhambata-FordSJonkerDJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008;359:1757–1765.
LievreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol2008;26:374–379.
ArtaleSSartore-BianchiAVeroneseSM. Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol2008;26:4217–4219.
Etienne-GrimaldiMCFormentoJLFrancoualM. KRAS mutations in treatment outcome in colorectal cancer in patients receiving exclusive fluoropyrimidine. Clin Cancer Res2008;14:4830–4835.
NelsonHPetrelliNCarlinA. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst2001;93:583–596.
KapiteijnEMarijnenCANagtegaalID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med2001;345:638–646.
SchoellhammerHFGregorianACSarkisyanGGPetrieBA. How important is rigid proctosigmoidoscopy in localizing rectal cancer. Am J Surg2008;186:904–908.
BaxterNNGarcia-AguilarJ. Organ preservation for rectal cancer. J Clin Oncol2007;25:1014–1020.
WeiserMRLandmannRGWongWD. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum2005;48:1169–1175.
WiigJNLarsenSGGierckskyKE. Operative treatment of locally recurrent rectal cancer. Recent Results Cancer Res2005;165:136–147.
BartramCBrownG. Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol Clin North Am2002;31:827–839.
BipatSGlasASSlorsFJ. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology2004;232:773–783.
KlessenCRogallaPTaupitzM. Local staging of rectal cancer: the current role of MRI. Eur Radiol2007;17:379–389.
LahayeMJEngelenSMNelemansPJ. Imaging for predicting the risk factors—the circumferential resection margin and nodal disease—of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR2005;26:259–268.
Beets-TanRGVliegenRFBeetsGL. Magnetic resonance imaging of rectal cancer: what radiation oncologists need to know. Front Radiat Ther Oncol2004;38:1–12.
GuillemJGCohenAM. Current issues in colorectal cancer surgery. Semin Oncol1999;26:505–513.
YouYNBaxterNNStewartANelsonH. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg2007;245:726–733.
LandmannRGWongWDHoepflJ. Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum2007;50:1520–1525.
NashGMWeiserMRGuillemJG. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum2009;52:577–582.
JayneDGGuillouThorpeH. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol2007;25:3061–3068.
NgSSLeungKLLeeJF. Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomized trial. Ann Surg Oncol2008;15:2418–2425.
WagmanLJ. Laparoscopic and open surgery for colorectal cancer: reaching equipoise?J Clin Oncol2007;25:2996–2998.
HealdRJHusbandEMRyallRD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?Br J Surg1982;69:613–616.
ParfittJRDrimanDK. The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol2007;60:849–855.
NagetgaalIDvan de VeldeCJHvan der WorpE. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol2002;20:1729–1734.
MarrRBirbeckKGarvicanJ. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg2005;242:74–82.
PahlmanLBoheMCedermarkB. The Swedish rectal cancer registry. Br J Surg2007;94:1285–1292.
den DulkMPutterHColletteL. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur J Cancer2009;45:1175–1183.
SteupWHMoriyaYvan de veldeCJH. Patterns of lymphatic spread in rectal cancer. A topographical analysis on lymph node metastases. Eur J Cancer2002;38:911–918.
SchlagPM. Surgical sphincter preservation in rectal cancer. Oncologist1996;1:288–292.
WagmanRMinskyBDCohenAM. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys1998;42:51–57.
SauerRBeckerHHohenbergerW. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med2004;351:1731–1740.
KachnicLA. Should preoperative or postoperative therapy be administered in the management of rectal cancer?Semin Oncol2006;33(Suppl 11):S64–69.
MadoffRD. Chemoradiotherapy for rectal cancer—when, why, and how?N Engl J Med2004;351:1790–1792.
GuillemJGDiaz-GonzolezJAMinskyB. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol2008;26:368–373.
Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med1997;336:980–987.
Colorectal Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet2001;358:1291–1304.
PeetersKCMJMarijnenCAMNagtegaalID. The TME trial after a median follow-up of 6 years. Ann Surg2007;246:693–701.
Sebag-MontefioreDStephensRJSteeleR. Prooperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet2009;373:811–820.
GerardJPConroyTBonnetainF. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol2006;24:4620–4625.
CeelenWPvan NieuwenhoveYFierensK. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer (review). Cochrane Database Syst Rev2009;CD006041.
Glynne-JonesRSebag-MontefioreD. Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study. J Clin Oncol2006;24:4664–4665; author reply 4665–4666.
BossetJFCalaisGMineurL. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol2005;23:5620–5627.
BossetJFColletteLCalaisG. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med2006;355:1114–1123.
ColletteLBossetJFden DulkM. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the EORTC Group. J Clin Oncol2007;25:4379–4386.
BujkoKKepkaLMichalskiWNowackiMP. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol2006;80:4–12.
WongRKTandanVDe SilvaSFigueredoA. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev2007:CD002102.
PeetersKCvan de VeldeCJLeerJW. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol2005;23:6199–6206.
TepperJEO’ConnellMNiedzwieckiD. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol2002;20:1744–1750.
GundersonLLSargentDJTepperJE. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol2004;22:1785–1796.
JohalBSPhangPMcGahanC. Treatment patterns and outcomes of patients with pT3N0 rectal cancer in a population-based setting [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4039.
SmalleySRBenedettiJKWilliamsonSK. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol2006;24:3542–3547.
O’ConnellMJMartensonJAWieandHS. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med1994;331:502–507.
AndreTBoniCNavarro. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol2009;27:3109–3116.
TwelvesCWongANowackiMP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med2005;352:2696–2704.
HongTSRitterMATomeWAHarariPM. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer2005;92:1819–1824.
MeyerJCzitoBYinFFWillettC. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. Clin Colorectal Cancer2007;6:348–356.
American College of Radiology. Practice Guideline for Intensity-modulated radiation therapy (IMRT) 2007; Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/ro/imrt.aspx. Accessed July 2009
ValentiVBalducciMTororetoF. Intraoperative radiotherapy: current thinking. Eur J Surg Oncol2002;28:180–185.
HahnloserDHaddockMGNelsonH. Intraoperative radiotherapy in the multimodality approach to colorectal cancer. Surg Oncol Clin N Am2003;12:993–1013.
WillettCGCzitoBGTylerDS. Intraoperative radiation therapy. J Clin Oncol2007;25:971–977.
MooreHGGittlemanAEMinskyBD. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum2004;47:279–286.
Habr-GamaAPerezROProscurshimI. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?Int J Radiat Oncol Biol Phys2008;71:1181–1188.
TulchinskyHShmuellEGigerA. An interval > 7 weeks between neoadjuvant theapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol2008;15:2661–2667.
TranCLUdaniSHoltAArnellT. Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg2006;192:873–877.
WolmarkNWieandHSHyamsDM. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst2000;92:388–396.
BensonABIII. New approaches to the adjuvant therapy of colon cancer. Oncologist2006;11:973–980.
MinskyBDGuillemJG. Multidisciplinary management of resectable rectal cancer: new developments and controversies. Oncology (Williston Park)2008;22:1430–1437.
FakihM. Treating rectal cancer: key issues reconsidered. Oncology (Williston Park)2008;22:1444–1446.
BensonABIII. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res2007;13:6913s–6920s.
SenguptaSTjandraJJ. Local excision of rectal cancer: what is the evidence?Dis Colon Rectum2001;44:1345–1361.
Garcia-AguilarJMellgrenASirivongsP. Local excision of rectal cancer without adjuvant therapy: a word of caution. Ann Surg2000;231:345–351.
WillettCGComptonCCShellitoPCEfirdJT. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer1994;73:2716–2720.
Van CutsemENordlingerBAdamR. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer2006;42:2212–2221.
YooPSLopez-SolerRILongoWEChaCH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer2006;6:202–207.
KemenyN. Management of liver metastases from colorectal cancer. Oncology (Williston Park)2006;20:1161–11761179.
MuratoreAZorziDBouzariH. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?Ann Surg Oncol2007;14:766–770.
AlbertsSRHorvathWLSternfeldWC. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol2005;23:9243–9249.
FongYCohenAMFortnerJG. Liver resection for colorectal metastases. J Clin Oncol1997;15:938–946.
TsaiMSuYHoM. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol2007;14:786–794.
PoultsidesGAServaisELSaltzLB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol2009;27:3379–3384.
FosterJH. Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis1984;4:170–179.
StanglRAltendorf-HofmannACharnleyRMScheeleJ. Factors influencing the natural history of colorectal liver metastases. Lancet1994;343:1405–1410.
VenookAP. The Kemeny article reviewed. Oncology2006;20:477–484.
ChotiMASitzmannJVTiburiMF. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg2002;235:759–766.
PawlikTMPoonRTAbdallaEK. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg2005;140:450–457; discussion 457–458.
CharnsangavejCClaryBFongY. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1261–1268.
VautheyJNZorziDPawlikTM. Making unresectable hepatic colorectal metastases resectable—does it work?Semin Oncol2005;32(Suppl 9):S118–122.
PozzoCBassoMCassanoA. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol2004;15:933–939.
Altendorf-HofmannAScheeleJ. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am2003;12:165–192.
PawlikTMSchulickRDChotiMA. Expanding criteria for resectability of colorectal liver metastases. Oncologist2008;13:51–64.
FolprechtGGrotheyAAlbertsS. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol2005;16:1311–1319.
ReddySKPawlikTMZorziD. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol2007;14:3481–3491.
CoveyAMBrownKTJarnaginWR. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg2008;247:451–455.
AdamRMillerRPitomboM. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am2007;16:525–536.
AbdallaEK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg2009;197:737–739.
AbdallaEKVautheyJNEllisLM. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg2004;239:818–825.
HurHKoYTMinBS. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg2009;197:728–736.
GleisnerALChotiMAAssumpcaoL. Colorectal liver metastases: recurrence and survival following hepatic resectin, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg2008;143:1204–1212.
ReuterNPWoodallCEScogginsCR. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent?J Gastrointest Surg2009;13:486–491.
LeonardGDBrennerBKemenyNE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol2005;23:2038–2048.
BenoistSBrouquetAPennaC. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol2006;24:3939–3945.
BilchikAJPostonGCurleySA. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol2005;23:9073–9078.
AdamRAvisarEAricheA. Five-year survival following hepatic resecton after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol2001;8:347–353.
RivoireMDe CianFMeeusP. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer2002;95:2283–2292.
VautheyJNPawlikTMRiberoD. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol2006;24:2065–2072.
PawlikTMOlinoKGleisnerAL. Preoperative chemotheapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg2007;11:860–888.
PawlikTMScogginsCRZorziD. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg2005;241:715–722.
EliasDLiberaleGVernereyD. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol2005;12:900–909.
FongYSaloJ. Surgical therapy of hepatic colorectal metastasis. Semin Oncol1999;26:514–523.
AdamRDelvartVPascalG. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg2004;240:644–657.
DelaunoitTAlbertsSRSargentDJ. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol2005;16:425–429.
NordlingerBSorbyeHGlimeliusB. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet2008;37:1007–1016.
TanBRZubalBHawkinsw. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases [abstract]. Prestented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 497.
FolprechtGGruenbergerTHartmannJT. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study) [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17 2009; San Francisco, California. Abstract 296.
SouglakosJAndroulakisNSyrigosK. FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer2006;94:798–805.
FalconeARicciSBrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:1670–1676.
ScappaticciFAFehrenbacherLCartwrightT. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol2005;91:173–180.
Package Insert. Bevacizumab. South San Francisco, CAGenentech, Inc.October2006.
GruenbergerBTamandlDSchuellerJ. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol2008;26:1830–1835.
ReddySKMorseMAHurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:96–106.
LeeWSYunSHChunHK. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis2007;22:699–704.
HeadrickJRMillerDLNagorneyDM. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg2001;71:975–979; discussion 979–980.
KemenyN. Management of liver metastases from colorectal cancer. Oncology (Williston Park)2006;20:1161–11761179.
KemenyNHuangYCohenAM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med1999;341:2039–2048.
KemenyNEGonenM. Hepatic arterial infusion after liver resection. N Engl J Med2005;352:7:734–735.
MulcahyMFLewandowskiRJIbrahimSM. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer2009;115:1849–1858.
HongKMcBrideJDGeorgiadesCS. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol2009;20:360–367.
KatzAWCarey-SampsonMMuhsAG. Hypofractionated stereotactic body radiation therapy (SBRT) for patients with limited hepatic metastases. Int J Radiat Oncol Biol Phys2007;67:793–798.
YuT-KBhosalePRCraneCH. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Rad Oncol Biol Phys2008;71:1175–1180.
LowyAMRichTASkibberJM. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Ann Surg1996;223:177–185.
HoffmanJPRileyLCarpNZLitwinS. Isolated locally recurrent rectal cancer: a review of incidence, presentation, and management. Semin Oncol1993;20:506–519.
BartlettDLBerlinJLauwersGY. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1284–1292.
PelosiEDeandreisD. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol2007;33:1–6.
DresenRCGosensMJMartijnH. Radical resection after IORT-containing multimodality treatment is the most important determinant of outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol2008;15:1937–1947.
YanTDBlackDSavadyRSugarbakerPH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol2006;24:4011–4019.
EsquivelJSticcaRSugarbakerP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol2007;14:128–133.
SprangersMAGTaalBGAaronsonNK. Quality of life in colorectal cancer: stoma vs. nonstoma patients. Dis Colon Rectum1995;38:361–369.
LangeMMMassCPMarijnenCAM. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Cancer2008;95:1020–1028.
LangeMMMassCPMarijnenCAM. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer2009;45:1578–1588.
DeSnooLFaithfullS. A qualitative study of anterior resection syndrome: the experiences of cancer survivors who have undergone resection surgery. Eur J Cancer Care2006;15:244–251.
BaxterNNHabermannEBTepperJE. Risk of pelvic fractures in older women following pelvic irradiation. JAMA2005;294:2587–2593.
DenlingerCSBarsevickAM. The Challenges of Colorectal Cancer Survivorship. J Natl Cancer Netw2009;7:in press.
DignamJLPoliteBNYothersG. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst2006;98:1647–1654.
MeyerhardtJAHeseltineDNiedzwieckiD. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol2006;24:3535–3541.
MeyerhardtJANiedzwieckiDHollisD. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA2007;298:754–764.
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 0 | 0 | 0 |
Full Text Views | 210 | 210 | 30 |
PDF Downloads | 73 | 73 | 14 |
EPUB Downloads | 0 | 0 | 0 |